What You Should Know:
– VieCure Inc., pioneer of next-generation intelligence platforms that democratize community oncology care, today announced the completion of a $45 million financing led by Northpond Ventures and the appointment of industry veteran Richard Daly as chairman of the board of directors.
– The company will use the proceeds to scale commercial operations to meet the growing demand for its patented Halo Intelligence platform. This platform is the first AI-enabled community oncology care solution that combines clinical decision support and smart electronic medical records to help determine the right treatment path for every patient, every time. Over 18,000 patients are managed daily on the VieCure platform.
VieCure’s Halo Intelligence: Revolutionizing Precision Oncology with AI-Enabled Clinical Decision Support
VieCure is the leading provider of next-generation intelligence platforms for community oncology care. Its Halo Intelligence platform stands as the first AI-powered clinical decision support system, seamlessly integrated into a smart electronic medical record (EMR) platform, enabling clinicians to manage personalized treatment plans from cancer diagnosis through therapy and follow-up care. This platform addresses the increasing complexity of precision oncology, which now requires a multi-omic approach involving genomics, transcriptomics, proteomics, and epigenomics.
With the rapidly expanding volume of precision oncology data, healthcare professionals in community settings face significant challenges in identifying effective treatment options. VieCure’s Halo Intelligence platform is engineered to streamline this process, offering industry-leading, AI-enabled tools that assist oncologists in determining the optimal treatments based on each patient’s unique cancer profile.
The complete VieCure platform provides an integrated ecosystem of tools, including:
– an oncology information management system,
– an AI engine,
– mobile applications for both patients and physicians,
– a comprehensive codified content library,
– integrated telehealth features, and
– a modern analytics data environment.
At its core, the Halo Intelligence platform links every crucial element of cancer diagnostics and treatment. This includes:
– discrete patient data,
– physician notes and clinical records,
– treatment responses,
– radiology images,
– pathology-based tumor profiles,
– molecular characteristics, and
– data from wearable devices.
The seamless integration of artificial intelligence with clinician expertise ensures real-time insights that enhance clinical workflows, boost patient engagement, and ultimately improve outcomes.
Incoming Chairman Richard Daly, with over three decades of experience in healthcare and genomics, will further bolster the company’s growth. His leadership background includes over 10 years as CEO of DNAnexus and 13 years in senior executive roles at Baxter Laboratories.
“VieCure continues to pioneer value-based healthcare with the only fully integrated, AI-enabled platform capable of optimizing cancer treatments,” said Mr. Daly. “I’m looking forward to working with the team to help accelerate VieCure’s platform expansion across its national network of community cancer centers by supporting physicians and driving improved patient outcomes.”
